{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:56:29Z","timestamp":1776329789584,"version":"3.50.1"},"reference-count":27,"publisher":"Baskent University","issue":"Suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.6002\/ect.mesot2023.o29","type":"journal-issue","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T07:26:36Z","timestamp":1708068396000},"source":"Crossref","is-referenced-by-count":1,"title":[],"prefix":"10.6002","volume":"22","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant. 2011;11(3):450-462. doi:10.1111\/j.1600-6143.2010.03283.x","DOI":"10.1111\/j.1600-6143.2010.03283.x"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation. 2009;87(5):621-630. doi:10.1097\/TP.0b013e318197c17d","DOI":"10.1097\/TP.0b013e318197c17d"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9(3):527-535. doi:10.1111\/j.1600-6143.2008.02519.x","DOI":"10.1111\/j.1600-6143.2008.02519.x"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Sellar\u00e9s J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388-399. doi:10.1111\/j.1600-6143.2011.03840.x","DOI":"10.1111\/j.1600-6143.2011.03840.x"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Jamboti JS. BK virus nephropathy in renal transplant recipients. Nephrology (Carlton). 2016;21(8):647-654. doi:10.1111\/nep.12728","DOI":"10.1111\/nep.12728"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant. 2000;15(3):324-332. doi:10.1093\/ndt\/15.3.324","DOI":"10.1093\/ndt\/15.3.324"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol. 2002;13(8):2145-2151. doi:10.1097\/01.asn.0000023435.07320.81","DOI":"10.1097\/01.ASN.0000023435.07320.81"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Nankivell BJ, Renthawa J, Sharma RN, Kable K, O'Connell PJ, Chapman JR. BK virus nephropathy: histological evolution by sequential pathology. Am J Transplant. 2017;17(8):2065-2077. doi:10.1111\/ajt.14292","DOI":"10.1111\/ajt.14292"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Zakaria ZE, Elokely AM, Ghorab AA, et al. Screening for BK viremia\/viruria and the impact of management of BK virus nephropathy in renal transplant recipients. Exp Clin Transplant. 2019;17(Suppl 1):83-91. doi:10.6002\/ect.MESOT2018.O17","DOI":"10.6002\/ect.MESOT2018.O17"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Nickeleit V, Singh HK, Randhawa P, et al; Banff Working Group on Polyomavirus Nephropathy. The Banff Working Group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations. J Am Soc Nephrol. 2018;29(2):680-693. doi:10.1681\/ASN.2017050477","DOI":"10.1681\/ASN.2017050477"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347(7):488-496. doi:10.1056\/NEJMoa020439","DOI":"10.1056\/NEJMoa020439"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Hirsch HH. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant. 2002;2(1):25-30. doi:10.1034\/j.1600-6143.2002.020106.x","DOI":"10.1034\/j.1600-6143.2002.020106.x"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Randhawa PS, Demetris AJ. Nephropathy due to polyomavirus type BK. N Engl J Med. 2000;342(18):1361-1363. doi:10.1056\/NEJM200005043421809","DOI":"10.1056\/NEJM200005043421809"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005;5(3):582-594. doi:10.1111\/j.1600-6143.2005.00742.x","DOI":"10.1111\/j.1600-6143.2005.00742.x"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Hassan S, Mittal C, Amer S, Khalid F, et al. Currently recommended BK virus (BKV) plasma viral load cutoff of \u22654 log10\/mL underestimates the diagnosis of BKV-associated nephropathy: a single transplant center experience. Transpl Infect Dis. 2014;16(1):55-60. doi:10.1111\/tid.12164","DOI":"10.1111\/tid.12164"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Borni-Duval C, Caillard S, Olagne J, et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation. 2013;95(12):1498-1505. doi:10.1097\/TP.0b013e3182921995","DOI":"10.1097\/TP.0b013e3182921995"},{"key":"ref16","unstructured":"17. Soleymanian T, Rasulzadegan MH, Sotoodeh M, et al. Low prevalence of BK virus nephropathy on nonprotocol renal biopsies in Iranian kidney transplant recipients: one center's experience and review of the literature. Exp Clin Transplant. 2010;8(4):297-302."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Shen CL, Wu BS, Lien TJ, Yang AH, Yang CY. BK polyomavirus nephropathy in kidney transplantation: balancing rejection and infection. Viruses. 2021;13(3):487. doi:10.3390\/v13030487","DOI":"10.3390\/v13030487"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Bischof N, Hirsch HH, Wehmeier C, et al. Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long-term outcomes. Nephrol Dial Transplant. 2019;34(7):1240-1250. doi:10.1093\/ndt\/gfy346","DOI":"10.1093\/ndt\/gfy346"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation. 2010;89(9):1057-1070. doi:10.1097\/TP.0b013e3181d0e15e","DOI":"10.1097\/TP.0b013e3181d0e15e"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Keller N, Duquennoy S, Conrad A, et al. Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: a multicenter retrospective study. Transpl Infect Dis. 2019;21(2):e13058. doi:10.1111\/tid.13058","DOI":"10.1111\/tid.13058"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Randhawa PS, Schonder K, Shapiro R, Farasati N, Huang Y. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation. 2010;89(12):1462-1465. doi:10.1097\/tp.0b013e3181daaaf1","DOI":"10.1097\/TP.0b013e3181daaaf1"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Velay A, Solis M, Benotmane I, et al. Intravenous immunoglobulin administration significantly increases BKPyV genotype-specific neutralizing antibody titers in kidney transplant recipients. Antimicrob Agents Chemother. 2019;63(8):e00393-19. doi:10.1128\/AAC.00393-19","DOI":"10.1128\/AAC.00393-19"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Benotmane I, Solis M, Velay A, et al. Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients-Results from a proof-of-concept study. Am J Transplant. 2021;21(1):329-337. doi:10.1111\/ajt.16233","DOI":"10.1111\/ajt.16233"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Kable K, Davies CD, O'Connell PJ, Chapman JR, Nankivell BJ. Clearance of BK virus nephropathy by combination antiviral therapy with intravenous immunoglobulin. Transplant Direct. 2017;3(4):e142. doi:10.1097\/TXD.0000000000000641","DOI":"10.1097\/TXD.0000000000000641"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Raupp FVV, Meinerz G, da Silva CK, et al. BK Polyomavirus-associated nephropathy managed by screening policy in a real-life setting. Transpl Infect Dis. 2020;22(1):e13213. doi:10.1111\/tid.13213","DOI":"10.1111\/tid.13213"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Parajuli S, Astor BC, Kaufman D, et al. Which is more nephrotoxic for kidney transplants: BK nephropathy or rejection? Clin Transplant. 2018;32(4):e13216. doi:10.1111\/ctr.13216","DOI":"10.1111\/ctr.13216"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T01:47:59Z","timestamp":1708307279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/supplement\/2024\/22\/1\/1\/118\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":27,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.mesot2023.o29","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}